Literature DB >> 30847511

[Curing cancer and protecting the heart : Challenges in cardio-oncology in the era of modern tumor treatment].

C Hohmann1, S Baldus1, R Pfister2.   

Abstract

Recent advances in the medical oncological treatment options for cancer have led to a clear improvement in the survival rate worldwide; however, many of the recently developed new drugs are directly or indirectly associated with cardiovascular side effects. Cardiovascular diseases are already the most frequent non-cancerous cause of death in tumor patients. Prevention, early detection of these complications, correct management and timely initiation of specific cardiac medical treatment are the key for an improvement of the cardiovascular prognosis. This article provides an overview and comprehensive summary of the possible cardiotoxic side effects of important oncological therapies and offers possible practical strategies with respect to risk stratification, cardiological follow-up care and management approaches for chemotherapy-induced left ventricular dysfunction.

Entities:  

Keywords:  Cardiotoxicity; Drug therapy; Heart failure; Irradiation; Neoplasms

Mesh:

Substances:

Year:  2019        PMID: 30847511     DOI: 10.1007/s00059-019-4787-6

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  67 in total

1.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

2.  Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

Authors:  Michael S Ewer; Mary T Vooletich; Jean-Bernard Durand; Myrshia L Woods; Joseph R Davis; Vicente Valero; Daniel J Lenihan
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

3.  Moyamoya following cranial irradiation for primary brain tumors in children.

Authors:  N J Ullrich; R Robertson; D D Kinnamon; R M Scott; M W Kieran; C D Turner; S N Chi; L Goumnerova; M Proctor; N J Tarbell; K J Marcus; S L Pomeroy
Journal:  Neurology       Date:  2007-03-20       Impact factor: 9.910

4.  The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients.

Authors:  D Walsh; S Donnelly; L Rybicki
Journal:  Support Care Cancer       Date:  2000-05       Impact factor: 3.603

5.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

Authors:  G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

Review 6.  Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.

Authors:  Edward T H Yeh; Ann T Tong; Daniel J Lenihan; S Wamique Yusuf; Joseph Swafford; Christopher Champion; Jean-Bernard Durand; Harry Gibbs; Alireza Atef Zafarmand; Michael S Ewer
Journal:  Circulation       Date:  2004-06-29       Impact factor: 29.690

7.  The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.

Authors:  George Dranitsaris; Daniel Rayson; Mark Vincent; Jose Chang; Karen Gelmon; David Sandor; Greg Reardon
Journal:  Breast Cancer Res Treat       Date:  2007-11-03       Impact factor: 4.872

Review 8.  Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

Authors:  Melinda L Telli; Sharon A Hunt; Robert W Carlson; Alice E Guardino
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

Review 9.  Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Authors:  Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

10.  Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring.

Authors:  A L Jones; M Barlow; P J Barrett-Lee; P A Canney; I M Gilmour; S D Robb; C J Plummer; A M Wardley; M W Verrill
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more
  1 in total

Review 1.  Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship.

Authors:  Claudia de Wall; Johann Bauersachs; Dominik Berliner
Journal:  Clin Exp Metastasis       Date:  2021-06-12       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.